Inhibition of phosphodiesterase 4 enhances lung alveolarisation in neonatal mice exposed to hyperoxia

European Respiratory Journal

Volumn 33, Issue 4, 2009, Pages 861-870

  Woyda, K ^a   Koebrich, S ^a   Reiss, I ^d   Rudloff, S ^b   Pullamsetti, S S ^a,c   Ruhlmann A ^a   Weissmann, N ^a   Ghofrani, H A ^a   Gunther A ^a   Seeger, W ^a   Grimminger, F ^a   Morty, R E ^a   Schermuly, R T ^a,c  

^a JUSTUS LIEBIG UNIVERSITY GIESSEN   (Germany)

^b UNIVERSITY HOSPITAL GIESSEN   (Germany)

^c MAX PLANCK INSTITUTE FOR HEART AND LUNG RESEARCH   (Germany)

^d SOPHIA CHILDREN S HOSPITAL   (Netherlands)

Author keywords

Bronchopulmonary dysplasia; Cilomilast; Lung development; Neonatal chronic lung disease

Indexed keywords

CILOMILAST; MESSENGER RNA; OXYGEN; PHOSPHODIESTERASE I; PHOSPHODIESTERASE IV; PHOSPHODIESTERASE V;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BREATHING; C57BL MOUSE; CLINICAL FEATURE; CONTROLLED STUDY; DRUG DOSE COMPARISON; DRUG EFFECT; ENZYME INHIBITION; EXPOSURE; GROWTH; HYPEROXIA; IMMUNOBLOTTING; LUNG ALVEOLUS; LUNG ALVEOLUS WALL; LUNG COMPLIANCE; LUNG DEVELOPMENT; LUNG DYSPLASIA; MOUSE; NEWBORN; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; TREATMENT RESPONSE; UPREGULATION;

ANIMALS; ANIMALS, NEWBORN; BLOTTING, WESTERN; CYCLIC NUCLEOTIDE PHOSPHODIESTERASES, TYPE 4; HYPEROXIA; LUNG COMPLIANCE; MICE; MICE, INBRED C57BL; PHOSPHODIESTERASE INHIBITORS; PULMONARY ALVEOLI; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION;

EID: 63849134632     PISSN: 09031936     EISSN: 13993003     Source Type: Journal    
DOI: 10.1183/09031936.00109008     Document Type: Article

References (44)

1. Jobe AH, Ikegami M. Lung development and function in preterm infants in the surfactant treatment era. Annu Rev Physiol 2000; 62: 825-846.
2. Northway WH Jr, Rosan RC, Porter DY. Pulmonary disease following respirator therapy of hyaline-membrane disease. Bronchopulmonary dysplasia. N Engl J Med 1967; 276: 357-368.
3. Smith VC, Zupancic JA, McCormick MC, et al. Trends in severe bronchopulmonary dysplasia rates between 1994 and 2002. J Pediatr 2005; 146: 469-473.
4. Rojas MA, Gonzalez A, Bancalari E, Claure N, Poole C, Silva-Neto G. Changing trends in the epidemiology and pathogenesis of neonatal chronic lung disease. J Pediatr 1995; 126: 605-610.
5. Kinsella JP, Greenough A, Abman SH. Bronchopulmonary dysplasia. Lancet 2006; 367: 1421-1431.
6. Bourbon J, Boucherat O, Chailley-Heu B, Delacourt C. Control mechanisms of lung alveolar development and their disorders in bronchopulmonary dysplasia. Pediatr Res 2005; 57: 38R-46R.
7. Abman SH. Bronchopulmonary dysplasia: ''a vascular hypothesis''. Am J Respir Crit Care Med 2001; 164:1755-1756.
8. Thebaud B, Abman SH. Bronchopulmonary dysplasia: where have all the vessels gone? Roles of angiogenic growth factors in chronic lung disease. Am J Respir Crit Care Med 2007; 175: 978-985.
9. Mourani PM, Ivy DD, Gao D, Abman SH. Pulmonary vascular effects of inhaled nitric oxide and oxygen tension in bronchopulmonary dysplasia. Am J Respir Crit Care Med 2004; 170: 1006-1013.
10. Jobe AH, Bancalari E. Bronchopulmonary dysplasia. Am J Respir Crit Care Med 2001; 163: 1723-1729.
11. Bender AT, Beavo JA. Cyclic nucleotide phosphodiesterases: molecular regulation to clinical use. Pharmacol Rev 2006; 58: 488-520.
12. Soderling SH, Beavo JA. Regulation of cAMP and cGMP signaling: new phosphodiesterases and new functions. Curr Opin Cell Biol 2000; 12: 174-179.
13. Dent G, Magnussen H, Rabe KF. Cyclic nucleotide phosphodiesterases in the human lung. Lung 1994; 172: 129-146.
14. Nijjar MS. Role of cyclic AMP and related enzymes in rat lung growth and development. Biochim Biophys Acta 1979; 586: 464-472.
15. Galie N, Ghofrani HA, Torbicki A, et al. Sildenafil citrate therapy for pulmonary arterial hypertension. N Engl J Med 2005; 353: 2148-2157.
16. Schermuly RT, Kreisselmeier KP, Ghofrani HA, et al. Chronic sildenafil treatment inhibits monocrotaline- induced pulmonary hypertension in rats. Am J Respir Crit Care Med 2004; 169: 39-45.
17. Ladha F, Bonnet S, Eaton F, Hashimoto K, Korbutt G, Thebaud B. Sildenafil improves alveolar growth and pulmonary hypertension in hyperoxia-induced lung injury. Am J Respir Crit Care Med 2005; 172: 750-756.
18. Houslay MD. PDE4 cAMP-specific phosphodiesterases. Prog Nucleic Acid Res Mol Biol 2001; 69: 249-315.
19. Martina SD, Ismail MS, Vesta KS. Cilomilast: orally active selective phosphodiesterase-4 inhibitor for treatment of chronic obstructive pulmonary disease. Ann Pharmacother 2006; 40: 1822-1828.
20. ter Horst SA, Wagenaar GT, de Boer E, et al. Pentoxifylline reduces fibrin deposition and prolongs survival in neonatal hyperoxic lung injury. J Appl Physiol 2004; 97: 2014-2019.
21. Lauterbach R, Szymura-Oleksiak J, Pawlik D, Warchol J, Lisowska-Miszczyk I, Rytlewski K. Nebulized pentoxifylline for prevention of bronchopulmonary dysplasia in very low birth weight infants: a pilot clinical study. J Matern Fetal Neonatal Med 2006; 19: 433-438.
22. de Visser YP, Walther FJ, Laghmani EH, van Wijngaarden S, Nieuwland K, Wagenaar GT. Phosphodiesterase-4 inhibition attenuates pulmonary inflammation in neonatal lung injury. Eur Respir J 2008; 31: 633-644.
23. Schade I, Roth-Eichhorn S, Kasper M, et al. Benefit of phosphodiesterase 4 inhibitors as supplemental therapy after lung transplantation concerning their antiproliferative effects: an experimental study using a heterotopic rodent model. Transplantation 2002; 74: 326-334.
24. Alejandre-Alcazar MA, Kwapiszewska G, Reiss I, et al. Hyperoxia modulates TGF-β/BMP signaling in a mouse model of bronchopulmonary dysplasia. Am J Physiol Lung Cell Mol Physiol 2007; 292: L537-L549.
25. Voswinckel R, Motejl V, Fehrenbach A, et al. Characterisation of post-pneumonectomy lung growth in adult mice. Eur Respir J 2004; 24: 524-532.
26. Schermuly RT, Dony E, Ghofrani HA, et al. Reversal of experimental pulmonary hypertension by PDGF inhibition. J Clin Invest 2005; 115: 2811-2821.
27. Schermuly RT, Pullamsetti SS, Kwapiszewska G, et al. Phosphodiesterase 1 upregulation in pulmonary arterial hypertension: target for reverse-remodeling therapy. Circulation 2007; 115: 2331-2339.
28. Wagenaar GT, ter Horst SA, van Gastelen MA, et al. Gene expression profile and histopathology of experimental bronchopulmonary dysplasia induced by prolonged oxidative stress. Free Radic Biol Med 2004; 36: 782-801.
29. Ghofrani HA, Osterloh IH, Grimminger F. Sildenafil: from angina to erectile dysfunction to pulmonary hypertension and beyond. Nat Rev Drug Discov 2006; 5: 689-702.
30. Giembycz MA. Cilomilast: a second generation phosphodiesterase 4 inhibitor for asthma and chronic obstructive pulmonary disease. Expert Opin Investig Drugs 2001; 10:1361-1379.
31. Kroegel C, Foerster M. Phosphodiesterase-4 inhibitors as a novel approach for the treatment of respiratory disease: cilomilast. Expert Opin Investig Drugs 2007; 16: 109-124.
32. Amy RW, Bowes D, Burri PH, Haines J, Thurlbeck WM. Postnatal growth of the mouse lung. J Anat 1977; 124: 131-151.
33. Lipworth BJ. Phosphodiesterase-4 inhibitors for asthma and chronic obstructive pulmonary disease. Lancet 2005;365: 167-175.
34. Deng H, Mason SN, Auten RL Jr. Lung inflammation in hyperoxia can be prevented by antichemokine treatment in newborn rats. Am J Respir Crit Care Med 2000; 162: 2316-2323.
35. Brown DM, Hutchison L, Donaldson K, MacKenzie SJ, Dick CA, Stone V. The effect of oxidative stress on macrophages and lung epithelial cells: the role of phosphodiesterases 1 and 4. Toxicol Lett 2007; 168: 1-6.
36. Alejandre-Alcazar MA, Michiels-Corsten M, Vicencio AG, et al. TGF-β signaling is dynamically regulated during the alveolarization of rodent and human lungs. Dev Dyn 2008; 237: 259-269.
37. Lecart C, Cayabyab R, Buckley S, et al. Bioactive transforming growth factor-β in the lungs of extremely low birth- weight neonates predicts the need for home oxygen supplementation. Biol Neonate 2000; 77: 217-223.
38. Burgess JK, Oliver BG, Poniris MH, et al. A phosphodiesterase 4 inhibitor inhibits matrix protein deposition in airways in vitro. J Allergy Clin Immunol 2006; 118: 649-657.
39. Albertine KH, Jones GP, Starcher BC, et al. Chronic lung injury in preterm lambs. Disordered respiratory tract development. Am J Respir Crit Care Med 1999; 159: 945-958.
40. Chua F, Sly PD, Laurent GJ. Pediatric lung disease: from proteinases to pulmonary fibrosis. Pediatr Pulmonol 2005;39: 392-401.
41. Dunkern TR, Feurstein D, Rossi GA, Sabatini F, Hatzelmann A. Inhibition of TGF-β induced lung fibroblast to myofibroblast conversion by phosphodiesterase inhibiting drugs and activators of soluble guanylyl cyclase. Eur J Pharmacol 2007; 572: 12-22.
42. Mori H, Nose T, Ishitani K, et al. Phosphodiesterase 4 inhibitor GPD-1116 markedly attenuates the development of cigarette smoke-induced emphysema in senescence- accelerated mice P1 strain. Am J Physiol Lung Cell Mol Physiol 2008; 294: L196-L204.
43. Martin-Chouly CA, Astier A, Jacob C, Pruniaux MP, Bertrand C, Lagente V. Modulation of matrix met alloproteinase production from human lung fibroblasts by type 4 phosphodiesterase inhibitors. Life Sci 2004; 75: 823-840.
44. Johnson-Varghese L, Brodsky N, Bhandari V. Effect of antioxidants on apoptosis and cytokine release in fet al rat type II pneumocytes exposed to hyperoxia and nitric oxide. Cytokine 2004; 28: 10-16.